MyMedicalRecords Files Patent Infringement Complaint Against WebMD

MyMedicalRecords Files Patent Infringement Complaint Against WebMD 
LOS ANGELES, CA -- (Marketwire) -- 02/12/13 --  MyMedicalRecords,
Inc., a wholly owned subsidiary of MMRGlobal, Inc. (OTCQB: MMRF)
(collectively, "MMR"), today announced the filing of a complaint for
patent infringement against WebMD Health Corp. and its wholly owned
subsidiary, WebMD Health Services Group, Inc. ("WebMD"). The
complaint alleges that WebMD is infringing on MMR's Personal Health
Records patents including U.S. Patent No. 8,301,466, and as a result,
MMR is seeking monetary damages as well as a permanent injunction.
The complaint was filed in the United States District Court for the
Central District of California, case number CV 13-00979 (CAS/JCx), on
February 11, 2013, and will be available on the court's website   
The complaint alleges that WebMD provides health information services
to consumers and healthcare providers, as well as employers and
health plans through both their private and public portals. The
public portal, such as the one accessible at, also
allows consumers to review a variety of health and wellness
information. Starting in 2007, MyMedicalRecords began meeting with
WebMD. At that time, WebMD's private patient portal, called WebMD
Health Manager, allowed patients to enter certain health information
into an account and run a self-assessment. Since that time, WebMD has
changed WebMD Health Manager into an integrated, untethered and
consumer-controlled Personal Health Record (PHR), incorporating
features and functionality that are the subject of MMR's patents.  
With the assistance of the Liner firm, MMR is pursuing efforts to
monetize its patent portfolio and other IP by investigating potential
infringement of MMR's patents by entities such as retail pharmacies,
EHR and PHR vendors, laboratory systems, hospitals, physicians, and
other healthcare professionals.  
MMR is a leading provider of Personal Health Records,
MyEsafeDepositBox storage solutions, and MMRPro document management
and imaging systems for healthcare professionals. The MMR Patent
Portfolio includes seven issued U.S. patents as well as additional
applications and continuation applications including nearly 400
claims. MMR also has been g
ranted patents and has other pending
applications in countries of commercial interest including Australia,
Singapore, New Zealand, Mexico, Japan, Canada, Hong Kong, South
Korea, Israel, and European nations. The patents involve inventions
pertaining to Personal Health Records, Patient Portals and other
Electronic Health Record systems. 
Additionally, MMR holds biotech patents which, among other things,
pertain to the manufacturing of compositions for B-cell vaccines used
in the fight against lymphoma, and also anti-CD20 antibodies. MMR's
biotech patent portfolio, which was acquired through its 2009 reverse
merger with San Diego-based biotech company Favrille, Inc., currently
includes three U.S. patents (U.S. Patent numbers 6,911,204, 8,114,404
and 8,133,486) four U.S. pending patent applications, and numerous
additional patents and patent applications globally, as well as other
IP which is the subject of 13 million dollars in licensing
For additional information regarding the MyMedicalRecords, Inc.
complaint against WebMD, contact Ted Ward at Liner Grode Stein
Yankelevitz Sunshine Regenstreif & Taylor LLP at (310) 500-3384. 
About MMRGlobal
 MMRGlobal, Inc., through its wholly-owned operating
subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use
online Personal Health Records ("PHRs") and electronic safe deposit
box storage solutions, serving consumers, healthcare professionals,
employers, insurance companies, financial institutions, retail
pharmacies, and professional organizations and affinity groups. The
MyMedicalRecords PHR enables individuals and families to access their
medical records and other important documents, such as birth
certificates, passports, insurance policies and wills, anytime from
anywhere using the Internet. MyMedicalRecords is built on
proprietary, patented technologies to allow documents, images and
voicemail messages to be transmitted and stored in the system using a
variety of methods, including fax, phone, or file upload without
relying on any specific electronic medical record platform to
populate a user's account. The Company's professional offering,
MMRPro, is designed to give physicians' offices an easy and
cost-effective solution to digitizing paper-based medical records and
sharing them with patients through an integrated patient portal.
Through its merger with Favrille, Inc. in January 2009, the Company
acquired intellectual property biotech assets that include anti-CD20
antibodies and data and samples from its FavId(TM)/Specifid(TM)
vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's
lymphoma. To learn more about MMRGlobal, Inc. visit View demos and video tutorials of the Company's
products and services at 
Forward-Looking Statements 
 All statements in this press release
that are not strictly historical in nature, including, without
limitation, intellectual property enforcement actions, infringement
claims or litigation, intellectual property licenses, and future
performance, management's expectations, beliefs, intentions,
estimates or projections, constitute "forward-looking statements."
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the Company's actual
results to be materially different from historical results or from
any results expressed or implied by such forward-looking statements.
Some can be identified by the use of words (and their derivations)
such as "need," "possibility," "potential," "intend," "offer,"
"development," "if," "negotiate," "when," "begun," "believe,"
"achieve," "will," "estimate," "expect," "maintain," "plan," and
"continue," or the negative of these words. Actual outcomes and
results of operations and the timing of selected events may differ
materially from the results predicted, and any reported results
should not be considered as an indication of future performance. Such
statements are necessarily based on assumptions and estimates and are
subject to various risks and uncertainties, including those relating
to the possible invalidity of the underlying assumptions and
estimates and possible changes or developments in economic, business,
industry, market, legal and regulatory circumstances and conditions
and actions taken or omitted to be taken by third parties, including
customers, suppliers, business partners, potential licensees,
competitors and legislative, judicial and other governmental
authorities and officials. Factors that could cause or contribute to
such differences include, but are not limited to: unexpected outcomes
with respect to intellectual property enforcement actions, claims of
intellectual property infringement and general intellectual property
litigation; our ability to maintain, develop, monetize and protect
our patent portfolio for both the Company's health IT and
biotechnology intellectual property assets in the U.S. and
internationally; the timing of milestone payments in connection with
licensing our intellectual property; our ability to establish and
maintain strategic relationships; changes in our relationships with
our licensees; the risk the Company's products are not adopted or
viewed favorably by the healthcare community and consumer retail
ket; business prospects, results of operations or financial
condition; risks related to the current uncertainty and instability
in financial and lending markets, including global economic
uncertainties; the timing and volume of sales and installations; the
length of sales cycles and the installation process; the market's
acceptance of new product and service introductions; competitive
product offerings and promotions; changes in government laws and
regulations including the 2009 HITECH Act and changes in Meaningful
Use and the 2010 Affordable Care Act; future changes in tax
legislation and initiatives in the healthcare industry; undetected
errors in our products; the possibility of interruption at our data
centers; risks related to third party vendors; risks related to
obtaining and integrating third-party licensed technology; risks
related to a security breach by third parties; risks associated with
recruitment and retention of key personnel; other litigation matters;
uncertainties associated with doing business internationally across
borders and territories; and additional risks discussed in the
Company's filings with the Securities and Exchange Commission. The
Company is providing this information as of the date of this release
and, except as required by applicable law, does not undertake any
obligation to update any forward-looking statements contained in this
release as a result of new information, future events or otherwise.   
Michael Selsman
Public Communications Co.
(310) 922-7033 
Press spacebar to pause and continue. Press esc to stop.